Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.44
SVA's Cash-to-Debt is ranked lower than
76% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. SVA: 1.44 )
Ranked among companies with meaningful Cash-to-Debt only.
SVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.48  Med: 2.18 Max: N/A
Current: 1.44
Equity-to-Asset 0.56
SVA's Equity-to-Asset is ranked lower than
62% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SVA: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
SVA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.58 Max: 0.64
Current: 0.56
0.41
0.64
Piotroski F-Score: 2
Altman Z-Score: 2.27
Beneish M-Score: -2.66
WACC vs ROIC
3.92%
-7.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -10.48
SVA's Operating Margin % is ranked higher than
66% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. SVA: -10.48 )
Ranked among companies with meaningful Operating Margin % only.
SVA' s Operating Margin % Range Over the Past 10 Years
Min: -42.98  Med: 5.73 Max: 50.06
Current: -10.48
-42.98
50.06
Net Margin % -7.09
SVA's Net Margin % is ranked higher than
67% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. SVA: -7.09 )
Ranked among companies with meaningful Net Margin % only.
SVA' s Net Margin % Range Over the Past 10 Years
Min: -30.18  Med: -1.42 Max: 23.7
Current: -7.09
-30.18
23.7
ROE % -3.80
SVA's ROE % is ranked higher than
71% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. SVA: -3.80 )
Ranked among companies with meaningful ROE % only.
SVA' s ROE % Range Over the Past 10 Years
Min: -12  Med: -0.67 Max: 33.16
Current: -3.8
-12
33.16
ROA % -2.28
SVA's ROA % is ranked higher than
74% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. SVA: -2.28 )
Ranked among companies with meaningful ROA % only.
SVA' s ROA % Range Over the Past 10 Years
Min: -7  Med: -0.38 Max: 17.45
Current: -2.28
-7
17.45
ROC (Joel Greenblatt) % -5.59
SVA's ROC (Joel Greenblatt) % is ranked higher than
74% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. SVA: -5.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -27  Med: 5.76 Max: 137.02
Current: -5.59
-27
137.02
3-Year Revenue Growth Rate 10.10
SVA's 3-Year Revenue Growth Rate is ranked higher than
59% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. SVA: 10.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18.5 Max: 82.5
Current: 10.1
0
82.5
3-Year EPS without NRI Growth Rate -66.70
SVA's 3-Year EPS without NRI Growth Rate is ranked lower than
95% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. SVA: -66.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -13.9 Max: 141
Current: -66.7
0
141
GuruFocus has detected 3 Warning Signs with Sinovac Biotech Ltd $SVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SVA's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

SVA Guru Trades in Q2 2016

Jim Simons 1,396,100 sh (+4.61%)
» More
Q3 2016

SVA Guru Trades in Q3 2016

Jim Simons 1,475,000 sh (+5.65%)
» More
Q4 2016

SVA Guru Trades in Q4 2016

Jim Simons 1,524,800 sh (+3.38%)
» More
Q1 2017

SVA Guru Trades in Q1 2017

Jim Simons 1,679,490 sh (+10.14%)
» More
» Details

Insider Trades

Latest Guru Trades with SVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SELB, NAS:OBSV, OTCPK:TYMI, NAS:DVAX, NAS:PETX, AMEX:MTNB, OTCPK:CKPT, NAS:IDRA, OTCPK:MXDHF, OTCPK:NICXF, NAS:KMDA, NAS:VCYT, OTCPK:SIGA, OTCPK:CLVLF, NAS:ABEO, NAS:VYGR, NAS:NK, NAS:CGEN, NAS:ARDX, NAS:CRIS » details
Traded in other countries:SVQ.Germany,
Headquarter Location:China
Sinovac Biotech Ltd is a biopharmaceutical company engaged in research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases.

Sinovac Biotech Ltd, formerly known as Net-Force System Inc., was incorporated in Antigua and Barbuda on March 1, 1999. The Company is an integrated China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A, hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza and mumps, as well as animal rabies vaccine. The Company is engaged in the development, manufacturing and sales of vaccines for infectious diseases. Its product consist of Healive, for the treatment of Hepatitis A; Bilive, for the treatment of Hepatitis A&B; Anflu, for the treatment of Influenza; Panflu Whole Viron Pandemic Influenza Vaccine, for Pandemic Influenza Virus; Split Viron Pandemic Influenza Vaccine, for the treatment of Pandemic Influenza Virus; Panflu.1, for the treatment of Influenza A H1N1 virus; RabEnd, for the treatment of Rabies Virus in animals; Mumps Vaccine, for the treatment of mumps; EV71 Vaccine, Pneumococcal Polysaccharide Vaccine, Varicella Vaccine, for the treatment of varicella-zoster virus, H7N9 Vaccine, for the treatment of H7N9 influenza. The Company has four manufacturing bases located in Haidian and Changping Districts of Beijing, Dalian City of Liaoning Province, and Tangshan City of Hebei Province and also has two upstream production facilities in Haidian District, Beijing. It has built a new production site in in Changping District, Beijing, which comprises a new filing and packaging line that complies with the new PRC GMP standards, EV71 production facilities and a warehouse. The Company relies on its sales force to sell its products directly to CDCs in the private market. As of December 31, 2013, the in-house sales and marketing team consisted of 170 staff members located in 31 provinces throughout China. The Company obtains the raw materials from local and overseas suppliers. It maintains two suppliers for each key raw material, with the exception of hepatitis B antigens for Bilive production. The hepatitis B antigens are sourced from Beijing Temple of Heaven. The Company competes with Kunming Institute of Biological Product, Pukang Biological Co., Ltd., Changchun Institute of Biological Products and Changchun Changsheng Life Sciences Ltd for hepatitis A vaccine. It competes with Hualan Biological Engineering Inc., Changchun Institute of Biological Products, GSK, Aleph Biological Co., Ltd. and Zhejiang Tianyuan for influenza vaccines. The Company is subject to PRC laws and regulations governing the use, manufacture, storage, handling or disposal of hazardous materials and waste products.

Top Ranked Articles about Sinovac Biotech Ltd

Sernova Completes Private Placement of $4,200,000

LONDON, ONTARIO--(Marketwired - Jun 30, 2016) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH) is pleased to announce that it has completed a non-brokered private placement of $4.2 million, pursuant to which Sernova issued a total of 16,800,000 units in two closing (June 27, 2016 and June 30, 2016). Each unit issued in the private placement consists of one common share and one common share purchase warrant, and each warrant is exercisable into one share at a price of $0.35 per share for a 24 month exercise period, subject to abridgement of the exercise period (after the expiry of the 4 month hold period) on 30 days notice to holders in the event that the 20-day volume weighted price of the shares exceeds $0.50. The gross proceeds from the private placement will be used to fund a US-based clinical trial ($2.5 million is allocated) and to fund Sernova's research and development programs including corporate and academic collaborations ($1.2 million is allocated) utilizing its platform technology to treat diabetes and other serious disease conditions, as well as for general corporate purposes (approximately $0.5 million). The Company compensated finders by way of cash fees of $130,462.50 and 521,850 non-transferable finder warrants, each such finder warrant having the same terms as the Unit warrants. Finders were Richardson GMP, Echelon Wealth Partners, Gravitas Securities Inc., Aventine Management Group, Raymond James, Mackie Research Capital Corporation, Canaccord Genuity, CMF AG and CRF Finance AG. All of the securities issued in connection with the private placement are subject to a four month hold period from the date of issuance in accordance with applicable provincial securities laws in Canada. The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed. This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 or any state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act of 1933 and all applicable state securities laws, or an applicable exemption from registration requirements. About Sernova Sernova Corp is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System™, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells), which then release proteins and/or hormones as required for the treatment of disease. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Forward-Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Specifically, although the company intends to expend the proceeds from the private placement as described above, there may be circumstances where for sound business reasons, a reallocation of funds may be deemed prudent or necessary. While actual expenditures may differ from the above amounts and allocations, the net proceeds will be used by the company in furtherance of its business. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.





Philip Toleikis, Ph.D.
President and CEO
(604) 961-2939
[email protected]
[email protected]
www.sernova.com
Ray Matthews & Associates
(604) 818-7778
www.raymatthews.ca




Read more...
Sernova Increases Private Placement to $4,200,000

LONDON, ONTARIO--(Marketwired - Jun 29, 2016) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH) is pleased to announce that it is increasing its non-brokered private placement to $4,200,000, equal to 16,800,000 units (the "Units") at $0.25 per Unit, to accommodate additional over-subscriptions (see our news releases dated June 27, 2016 and June 21, 2016 for further information about the private placement). Sernova issued 8,000,000 Units for $2,000,000 in the first closing on June 27, 2016 and expects to close the balance of the private placement, being 8,800,000 Units for $2,200,000, in a second and final closing on June 30, 2016. Each Unit consists of one common share and one common share purchase warrant, with each warrant exercisable into one share at a price of $0.30 per share for a 24 month exercise period, subject to abridgement of the exercise period (after the expiry of the 4 month hold period) on 30 days notice to holders in the event that the twenty-day volume weighted price of the shares exceeds $0.50. Completion of the private placement is subject to the receipt of the approval of the TSX Venture Exchange. All securities issued in connection with the private placement will be subject to a statutory hold period of four months. The Company expects to compensate finders on a portion of the increased private placement consisting of 7% in cash and 7% in finder warrants, or a combination thereof. This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 or any state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act of 1933 and all applicable state securities laws, or an applicable exemption from registration requirements. About Sernova Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System™, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells), which then release proteins and/or hormones as required. Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch System™ and our cell technologies, are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.





Sernova Corp.
Philip Toleikis, Ph.D.
President and CEO
(604) 961-2939
[email protected] / [email protected]
www.sernova.com
Ray Matthews & Associates
Suite 601-128 West Cordova Street
Vancouver, BC V6B 0E6
(604) 818-7778
www.raymatthews.ca




Read more...
Simavita Secures $7.3m in Funding

SYDNEY, AUSTRALIA--(Marketwired - Jun 29, 2016) - Simavita Limited ("Simavita" or the "Company") (TSX VENTURE:SV)(ASX:SVA) is pleased to announce that as a result of significant support from its shareholders it had raised $7,353,000. This funding is critical to the significant changes that the company is undertaking to reduce its cost structure, deliver new product and to significantly increase sales. Mr Michael Spooner, Non-Executive Chairman said "We are very firmly focused on turning the operations of the Company around. This financing provides an opportunity for the Company to focus squarely on delivering results. Our plans are clear, to introduce a much simpler product as quickly as is possible. We are focused on making sure that our products are perceived as providing a real value add to the management of people with incontinence and to their carers." For further information, please check our website (www.simavita.com). The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange not its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.





Ms Peta Jurd
E: [email protected]
T: 61 421 466 653
www.simavita.com




Read more...
CORRECTION FROM SOURCE: Sernova Increases Private Placement to $4,200,000

LONDON, ONTARIO--(Marketwired - Jun 29, 2016) - This document corrects and replaces the press release that was sent today at 06:15 ET. Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH) is pleased to announce that it is increasing its non-brokered private placement to $4,200,000, equal to 16,800,000 units (the "Units") at $0.25 per Unit, to accommodate additional over-subscriptions (see our news releases dated June 27, 2016 and June 21, 2016 for further information about the private placement). Sernova issued 8,000,000 Units for $2,000,000 in the first closing on June 27, 2016 and expects to close the balance of the private placement, being 8,800,000 Units for $2,200,000, in a second and final closing on June 30, 2016. Each Unit consists of one common share and one common share purchase warrant, with each warrant exercisable into one share at a price of $0.35 per share for a 24 month exercise period, subject to abridgement of the exercise period (after the expiry of the 4 month hold period) on 30 days notice to holders in the event that the twenty-day volume weighted price of the shares exceeds $0.50. Completion of the private placement is subject to the receipt of the approval of the TSX Venture Exchange. All securities issued in connection with the private placement will be subject to a statutory hold period of four months. The Company expects to compensate finders on a portion of the increased private placement consisting of 7% in cash and 7% in finder warrants, or a combination thereof. This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 or any state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act of 1933 and all applicable state securities laws, or an applicable exemption from registration requirements. About Sernova Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System™, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells), which then release proteins and/or hormones as required. Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch System™ and our cell technologies, are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.





Sernova Corp.
Philip Toleikis, Ph.D.
President and CEO
(604) 961-2939
[email protected] / [email protected]
www.sernova.com
Ray Matthews & Associates
Suite 601-128 West Cordova Street
Vancouver, BC V6B 0E6
(604) 818-7778
www.raymatthews.ca




Read more...
Sernova Announces $2,000,000 First Closing of Private Placement

Due to Oversubscription, Offering Increased to $3,750,000

LONDON, ONTARIO--(Marketwired - Jun 27, 2016) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH) is pleased to announce that it is closing today $2,000,000 of its non-brokered private placement announced on June 21, 2016. In addition, as the Company has received over-subscriptions of $1,650,000, it is increasing the total amount of the non-brokered private placement offering to $3,750,000 for a total offering of 15,000,000 units (the "Units") at $0.25 per Unit. The Company plans to close the balance of the placement, Thursday, June 30th, 2016. "We are pleased with the very strong interest from investors in Sernova's future in the regenerative medicine space as indicated by the oversubscription of the private placement," said Dr. Philip Toleikis, President and CEO of Sernova. Net proceeds from the private placement will be used to fund Sernova's regenerative medicine clinical program and collaborations utilizing the Company's platform technology to treat diabetes and other serious disease conditions, as well as for general corporate purposes. In the first closing today, Sernova will issue 8,000,000 Units at $0.25 per Unit for gross proceeds of $2,000,000. Each Unit to be issued will consist of one common share and one common share purchase warrant, with each warrant exercisable into one share at a price of $0.35 per share for a 24 month exercise period, subject to abridgement of the exercise period (after the expiry of the 4 month hold period) on 30 days notice to holders in the event that the twenty-day volume weighted price of the shares exceeds $0.50. Also, in respect of the first closing, the Company expects to compensate finders by way of cash fees of $132,912.50 and 531,650 non-transferable finder warrants, each such finder warrant having the same terms as the Unit warrants. The Company may also compensate finders on a portion of the increased private placement consisting of 7% in cash and 7% in finder warrants, or a combination thereof. Completion of the $3,750,000 private placement is subject to the receipt of the approval of the TSX Venture Exchange. All securities issued in connection with the private placement will be subject to a statutory hold period of four months. This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 or any state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act of 1933 and all applicable state securities laws, or an applicable exemption from registration requirements. About Sernova Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System™, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells), which then release proteins and/or hormones as required. Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch System™ and our cell technologies, are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.





Sernova Corp.
Philip Toleikis, Ph.D.
President and CEO
(604) 961-2939
[email protected] / [email protected]
www.sernova.com
Ray Matthews & Associates
Suite 601-128 West Cordova Street
Vancouver, BC V6B 0E6
(604) 818-7778
www.raymatthews.ca




Read more...
Simavita Limited: 2016 Special General Meeting Results

SYDNEY, AUSTRALIA--(Marketwired - Jun 23, 2016) - Simavita Limited ("Simavita" or the "Company") (TSX VENTURE:SV)(ASX:SVA) is pleased to announce the results of the Special Meeting of the Company's shareholders which was held at 10:00 am today (Australian Eastern Standard Time) in Sydney, Australia. All nine resolutions that were put before the meeting were passed on a show of hands. Details of the proxy votes received by the Company in relation to each resolution in the notice of special meeting and information circular are attached. For further information, please check our website (www.simavita.com). About Simavita Simavita is a medical device company operating in the digital healthcare sector that has developed an innovative, world first solution for the management of urinary incontinence, with a focus on the elderly. The first product is the SIM™ incontinence diagnostic tool kit which is an instrumented incontinence assessment application that provides evidence based incontinence management care plans to the residential aged care market. About SIM™ SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect record and report incontinence events during a compulsory or recommended assessment period in residential aged care sites to develop an evidence-based incontinence care plan. Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit www.simavita.com. The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange not its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.


SIMAVITA LIMITED


SPECIAL MEETING OF


SHAREHOLDERS HELD


ON JUNE 23, 2016





PROXY RESULTS





RESOLUTIONS
NUMBER OF SHARES
PERCENTAGE OF VOTES CAST









FOR
AGAINST
ABSTAIN
EXCLUDED
NON VOTE
FOR
AGAINST
WITHHELD/ ABSTAIN


1.
Approval and Authorization of the operation of the Conversion Mechanism in the Convertible Note Deeds
55,646,847
29,444
5,127
0
0
99.94%
0.05%
0.01%














2.
Approval and Authorization of the operation of the Conversion Mechanism in the Convertible Note Deeds for Dussman Pty. Ltd.
17,481,916
34,244
5,127
38,160,131
0
99.78%
0.20%
0.03%














3.
Approval and Authorization of the operation of the Conversion Mechanism in the Convertible Note Deeds for Holland Family Trust
55,614,047
32,244
5,127
30,000
0
99.93%
0.06%
0.01%














4.
Approval and Authorization of the operation of the Conversion Mechanism in the Convertible Note Deeds for Bingham Investments Pty. Ltd.
55,644,047
32,244
5,127
0
0
99.93%
0.06%
0.01%














5.
Approval and Authorization of the operation of the Conversion Mechanism in the Convertible Note Deeds for the Michael Brown Superannuation Fund
55,642,047
34,244
5,127
0
0
99.93%
0.06%
0.01%














6.
Approval and Authorization of the issuance of up to 138,740,000 CDIs
45,739,319
41,571
0
9,900,528
0
99.91%
0.09%
0.00%














7.
Approval and Authorization to grant to Mr. Michael Spooner up to 7,603,422 unlisted options
54,476,323
995,429
109,666
0
100,000
98.01%
1.79%
0.20%














8.
Approval and Authorization to grant to Dr. Gary Pace up to 7,603,422 unlisted options
54,576,323
995,429
109,666
0
0
98.02%
1.79%
0.20%














9.
Approval and Authorization to increase the total amount of potential aggregate directors' fees which may be paid to non-executive directors
49,405,237
5,840,046
433,485
0
2,650
88.73%
10.49%
0.78%









Simavita Limited
Ms Peta Jurd
61 421 466 653
[email protected]
www.simavita.com




Read more...
Sernova Announces Non-Brokered Private Placement

Net proceeds to fund Sernova's collaborations and a US-based clinical trial anticipated to commence in the second half of 2016

LONDON, ONTARIO--(Marketwired - Jun 21, 2016) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH) announced today that it has arranged a non-brokered private placement for gross proceeds of $2,000,000. The private placement consists of 8,000,000 units (the "Units") at a price of $0.25 per Unit. Each Unit will consist of one common share and one common share purchase warrant, with each warrant exercisable into one share at a price of $0.35 per share for a 24 month exercise period, subject to abridgement of the exercise period. Abridgement may occur with 30 days' notice to holders (after the expiry of the 4 month hold period) if the 20 day volume weighted price of SVA shares exceeds $0.50 per share. Net proceeds from the private placement will be used to fund Sernova's collaborations utilizing our Cell Pouch System platform technologies to treat diabetes and other serious disease conditions, as well as to support a US-based Phase I/II diabetes clinical trial anticipated to commence in the second half of 2016, and for general corporate purposes. All securities issued in connection with the private placement will be subject to a statutory hold period of four months. The Company will compensate finders on a portion of the private placement, such compensation consisting of 7% in cash or 7% in finder warrants, or a combination thereof. Completion of the private placement is subject to the receipt of all necessary corporate and regulatory approvals, including approval of the TSX Venture Exchange. About Sernova Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System™, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells), which then release proteins and/or hormones as required. Forward-Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made, which include our belief that Sernova will be able to raise additional capital to fund its clinical programs. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.





Sernova Corp.
Philip Toleikis, Ph.D.
President and CEO
(604) 961-2939
[email protected] / [email protected]
www.sernova.com
Ray Matthews & Associates
Suite 601-128 West Cordova Street
Vancouver, BC V6B 0E6
(604) 818-7778
www.raymatthews.ca




Read more...
Simavita Releases Unaudited Financial Statements and MD&A for the Nine-Month Period Ended March 31, 2016

SYDNEY, AUSTRALIA--(Marketwired - May 30, 2016) - Simavita Limited ("Simavita" or the "Company") (TSX VENTURE:SV) (ASX:SVA), a global leader in the digital healthcare sector, is pleased to release its financial results for the third quarter ended March 31, 2016, reported in Australian dollars and in accordance with International Financial Reporting Standards ("IFRS"). Quarterly highlights Notable highlights during the September quarter included:

Revenue from the sale of the Company's incontinence diagnostic tool kit of $178,174 representing an increase of 11% over the same prior year period.
The number of facilities at which Company's incontinence diagnostic tool kit has been deployed, or contracted to be deployed, continues to grow and as at date is 147. In North America some facilities are co-located on the same site. The number of sites has increased to 135 and the number of beds under contract has now passed 12,800.
Revenue for the period also included the first major sale in Europe through Danish distributor, Abena, who signed a contract to distribute the Company's incontinence diagnostic tool kit in the Municipality of Aarhus, Denmark.
Further strengthening the Company's global patent portfolio, with the filing of 6 new patents during the quarter bringing total patents filed to 34, including 32 granted patents.

Immediately post the quarter:

On April 27, 2016 the Company issued secured notes totalling $3,063,000. The terms of the secured note issue provide that the secured notes will automatically convert into CDIs on the Company obtaining shareholder approval. A Special General Meeting has been convened on 23 June 2016 to consider approval of this conversion. The conversion price under the secured notes is AUD$0.05.

About Simavita Simavita is a medical device company operating in the digital healthcare sector that has developed an innovative, world first solution for the management of urinary incontinence, with a focus on the elderly. The first product is the SIM™ incontinence diagnostic tool kit which is an instrumented incontinence assessment application that provides evidence based incontinence management care plans to the residential aged care market. About SIM™ SIM™ is a wireless sensor technology that delivers evidence-based instrumented incontinence data on individuals. It provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect, record and report incontinence events and related nursing interventions during a compulsory or recommended assessment period in residential aged care facilities; and to then develop evidence-based person-centred incontinence care plans. Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit www.simavita.com. The TSX Venture Exchange ("TSX-V") has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither the TSX-V nor its Regulation Services Provider (as that term is defined in policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this Release. Except for historical information, this announcement may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, the anticipated date of on the ASX, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Forward-Looking Information This document may contain "forward-looking information" within the meaning of Canadian securities laws ("forward-looking information"). This forward-looking information is given as of the date of this document. Forward-looking information relates to future events or future performance and reflects Simavita management's expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct. In certain cases, forward-looking information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or information that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita's interim and annual financial statements and management's discussion and analysis of those statements. Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.





Peta Jurd
Chief Commercial Officer
61 2 8405 6361
www.simavita.com




Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.48
SVA's PB Ratio is ranked higher than
61% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. SVA: 2.48 )
Ranked among companies with meaningful PB Ratio only.
SVA' s PB Ratio Range Over the Past 10 Years
Min: 0.73  Med: 2.43 Max: 9.91
Current: 2.48
0.73
9.91
PS Ratio 4.51
SVA's PS Ratio is ranked higher than
70% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. SVA: 4.51 )
Ranked among companies with meaningful PS Ratio only.
SVA' s PS Ratio Range Over the Past 10 Years
Min: 0.97  Med: 4.51 Max: 12.18
Current: 4.51
0.97
12.18
EV-to-EBIT -49.41
SVA's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. SVA: -49.41 )
Ranked among companies with meaningful EV-to-EBIT only.
SVA' s EV-to-EBIT Range Over the Past 10 Years
Min: -583.9  Med: 5.6 Max: 1667.3
Current: -49.41
-583.9
1667.3
EV-to-EBITDA -819.39
SVA's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. SVA: -819.39 )
Ranked among companies with meaningful EV-to-EBITDA only.
SVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1296  Med: 5.9 Max: 56.4
Current: -819.39
-1296
56.4
Shiller PE Ratio 96.38
SVA's Shiller PE Ratio is ranked lower than
75% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. SVA: 96.38 )
Ranked among companies with meaningful Shiller PE Ratio only.
SVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 81.33  Med: 122 Max: 519
Current: 96.38
81.33
519
Current Ratio 1.91
SVA's Current Ratio is ranked lower than
76% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. SVA: 1.91 )
Ranked among companies with meaningful Current Ratio only.
SVA' s Current Ratio Range Over the Past 10 Years
Min: 1.16  Med: 2.46 Max: 6.15
Current: 1.91
1.16
6.15
Quick Ratio 1.61
SVA's Quick Ratio is ranked lower than
74% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. SVA: 1.61 )
Ranked among companies with meaningful Quick Ratio only.
SVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.18 Max: 5.43
Current: 1.61
0.85
5.43
Days Inventory 344.50
SVA's Days Inventory is ranked lower than
87% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. SVA: 344.50 )
Ranked among companies with meaningful Days Inventory only.
SVA' s Days Inventory Range Over the Past 10 Years
Min: 125.96  Med: 201.85 Max: 389.63
Current: 344.5
125.96
389.63
Days Sales Outstanding 271.05
SVA's Days Sales Outstanding is ranked lower than
94% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. SVA: 271.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
SVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 108.21  Med: 176.39 Max: 271.05
Current: 271.05
108.21
271.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.10
SVA's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. SVA: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -70.9  Med: -6.25 Max: -0.6
Current: -1.1
-70.9
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 7.77
SVA's Price-to-Net-Current-Asset-Value is ranked lower than
65% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. SVA: 7.77 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SVA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.06  Med: 6.56 Max: 50.13
Current: 7.77
2.06
50.13
Price-to-Tangible-Book 2.50
SVA's Price-to-Tangible-Book is ranked higher than
68% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. SVA: 2.50 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SVA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.9  Med: 2.59 Max: 17.43
Current: 2.5
0.9
17.43
Price-to-Median-PS-Value 1.00
SVA's Price-to-Median-PS-Value is ranked lower than
61% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. SVA: 1.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 1.06 Max: 35.2
Current: 1
0.28
35.2
Earnings Yield (Greenblatt) % -2.03
SVA's Earnings Yield (Greenblatt) % is ranked higher than
63% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. SVA: -2.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.22  Med: 5.2 Max: 53.1
Current: -2.03
-2.22
53.1

More Statistics

Revenue (TTM) (Mil) $64.02
EPS (TTM) $ -0.08
Beta0.34
Short Percentage of Float0.68%
52-Week Range $4.60 - 6.45
Shares Outstanding (Mil)56.91
» More Articles for SVA

Headlines

Articles On GuruFocus.com
Sinovac Biotech Announces Receipt of NASDAQ Letter and Delayed Filing of Annual Report on Form 20-F May 16 2017 
Sinovac Reports Announces Filing Extension for 2016 Annual Report May 01 2017 
Sernova Completes Private Placement of $4,200,000 Jun 30 2016 
Sernova Increases Private Placement to $4,200,000 Jun 29 2016 
Simavita Secures $7.3m in Funding Jun 29 2016 
CORRECTION FROM SOURCE: Sernova Increases Private Placement to $4,200,000 Jun 29 2016 
Sernova Announces $2,000,000 First Closing of Private Placement Jun 27 2016 
Simavita Limited: 2016 Special General Meeting Results Jun 23 2016 
Sernova Announces Non-Brokered Private Placement Jun 21 2016 
Simavita Releases Unaudited Financial Statements and MD&A for the Nine-Month Period Ended March 31, May 30 2016 

More From Other Websites
INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Sinovac Biotech Ltd. and Encourages... May 19 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sinovac Biotech... May 19 2017
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Sinovac Biotech Ltd. and... May 18 2017
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Sinovac Biotech Ltd. Investors May 18 2017
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Sinovac Biotech Ltd. May 18 2017
Sinovac Biotech Ltd. (SVA) Investigated by Block & Leviton LLP For Securities Fraud After Revelation... May 18 2017
SINOVAC INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding... May 17 2017
EQUITY ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Sinovac Biotech Ltd.... May 17 2017
Sinovac Biotech Announces Receipt of NASDAQ Letter and Delayed Filing of Annual Report on Form 20-F May 16 2017
Sinovac Reports Announces Filing Extension for 2016 Annual Report May 01 2017
Sinovac Amends Shareholder Rights Plan Mar 24 2017
Sinovac Biotech Ltd. breached its 50 day moving average in a Bearish Manner : SVA-US : March 23,... Mar 23 2017
Sinovac Biotech Ltd. – Value Analysis (NASDAQ:SVA) : January 13, 2017 Jan 13 2017
Sinovac Biotech Ltd. breached its 50 day moving average in a Bullish Manner : SVA-US : January 12,... Jan 12 2017
INVESTOR ALERT: Lundin Law PC Announces an Investigation of Sinovac Biotech Ltd. and Encourages... Jan 11 2017
SINOVAC NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Jan 08 2017
INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sinovac Biotech... Jan 06 2017
SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Sinovac Biotech Ltd. and Encourages... Dec 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)